|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The digital world that we live today is filled with innovations and advanced technologies, but still the role of medical sectors in preventing infectious diseases like Tuberculosis is feeble- minded. One of the advanced technologies so called Nanotechnology plays a vital role in research for the diagnosis and treatment of Tuberculosis, thus preventing side effects and drug resistance. The present study aimed at evaluating, Norbornene derived Isoniazid Co polymer (NOR-PEG-INH) and Norbornene derived Rifampicin Co polymer (NOR-PEG-RIF), a novel nanocarrier along with the drug for Tuberculosis with targeted drug delivery and longer bioavailability. The nanocarrier along with the drug preparation and their property were studied by the collaborated institute, Indian Institute of Science Education and Research (IISER) by covalent binding method. The invitro activity of the drug was evaluated using absolute concentration method to observe the Mininium Inhibitory Concentration (MIC) of the drug against H37Rv control strain of Mycobacterium tuberculosis (MTB) and clinical isolates of Mycobacterium tuberculosis from patient samples. The results showed that NOR-PEG-INH and NOR-PEG-RIF, the nanocarriers of Isoniazid and Rifampicin were able to show the lower MIC to inhibit Mycobacterium tuberculosis.